{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sensitivity&page=15",
    "query": {
      "condition": "Sensitivity",
      "page": 15
    },
    "page_size": 10
  },
  "pagination": {
    "page": 15,
    "page_size": 10,
    "total_count": 4802,
    "total_pages": 481,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sensitivity&page=16&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sensitivity&page=14&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T22:05:45.683Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02919176",
      "title": "Brown Fat Activation Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Obese",
        "Metabolic Syndrome"
      ],
      "interventions": [
        {
          "name": "Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        },
        {
          "name": "Mirabegron and Pioglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Philip Kern",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "35 Years to 65 Years"
      },
      "enrollment_count": 39,
      "start_date": "2016-09-01",
      "completion_date": "2019-02-04",
      "has_results": false,
      "last_update_posted_date": "2020-02-07",
      "last_synced_at": "2026-10-21T22:05:45.683Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02919176"
    },
    {
      "nct_id": "NCT00274352",
      "title": "A Study of Adalimumab to Treat Sarcoidosis of the Skin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sarcoidosis"
      ],
      "interventions": [
        {
          "name": "adalimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pariser, Robert J., M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 16,
      "start_date": "2006-09",
      "completion_date": "2012-02",
      "has_results": false,
      "last_update_posted_date": "2013-05-22",
      "last_synced_at": "2026-10-21T22:05:45.683Z",
      "location_count": 1,
      "location_summary": "Norfolk, Virginia",
      "locations": [
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00274352"
    },
    {
      "nct_id": "NCT04476758",
      "title": "Immune Profiles in CF Fungal Infection",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cystic Fibrosis",
        "Fungal Infection",
        "Allergic Bronchopulmonary Aspergillosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "8 Years to 25 Years"
      },
      "enrollment_count": 24,
      "start_date": "2021-02-10",
      "completion_date": "2023-10-30",
      "has_results": false,
      "last_update_posted_date": "2024-07-18",
      "last_synced_at": "2026-10-21T22:05:45.683Z",
      "location_count": 1,
      "location_summary": "Highlands Ranch, Colorado",
      "locations": [
        {
          "city": "Highlands Ranch",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04476758"
    },
    {
      "nct_id": "NCT05848115",
      "title": "BiPAP in Pediatric Moderate to Severe Asthma Randomized Control Trial",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Asthma in Children"
      ],
      "interventions": [
        {
          "name": "Bi-level Positive Airway Pressure",
          "type": "DEVICE"
        },
        {
          "name": "Sham Bi-level Positive Airway Pressure",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 67,
      "start_date": "2023-06-23",
      "completion_date": "2025-07-07",
      "has_results": false,
      "last_update_posted_date": "2025-08-21",
      "last_synced_at": "2026-10-21T22:05:45.683Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05848115"
    },
    {
      "nct_id": "NCT01188876",
      "title": "Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "pralatrexate",
          "type": "DRUG"
        },
        {
          "name": "Folic Acid",
          "type": "DRUG"
        },
        {
          "name": "Vitamin B12 Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2010-08",
      "completion_date": "2017-07",
      "has_results": true,
      "last_update_posted_date": "2018-01-19",
      "last_synced_at": "2026-10-21T22:05:45.683Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01188876"
    },
    {
      "nct_id": "NCT05933499",
      "title": "Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Bimagrumab",
          "type": "DRUG"
        },
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "Calcium/Vitamin D",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Lifestyle and nutrition counseling",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT",
        "BEHAVIORAL"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2025-11-05",
      "completion_date": "2029-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-10-21T22:05:45.683Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05933499"
    },
    {
      "nct_id": "NCT02075255",
      "title": "Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Benralizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 220,
      "start_date": "2014-04-28",
      "completion_date": "2016-08-08",
      "has_results": true,
      "last_update_posted_date": "2018-06-08",
      "last_synced_at": "2026-10-21T22:05:45.683Z",
      "location_count": 20,
      "location_summary": "Los Angeles, California • Centennial, Colorado • Denver, Colorado + 16 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02075255"
    },
    {
      "nct_id": "NCT05718921",
      "title": "A Safety, Tolerability and Pharmacokinetics Study of Topical Ointment YR001 in Adult Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Atopic Dermatitis",
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "YR001 Dose A on low body surface area",
          "type": "DRUG"
        },
        {
          "name": "YR001 Dose A on middle body surface area",
          "type": "DRUG"
        },
        {
          "name": "YR001 Dose A on high body surface area",
          "type": "DRUG"
        },
        {
          "name": "YR001 Dose B on low body surface area",
          "type": "DRUG"
        },
        {
          "name": "YR001 Dose B on middle body surface area",
          "type": "DRUG"
        },
        {
          "name": "YR001 Dose B on high body surface area",
          "type": "DRUG"
        },
        {
          "name": "Placebo on low body surface area",
          "type": "DRUG"
        },
        {
          "name": "Placebo on middle body surface area",
          "type": "DRUG"
        },
        {
          "name": "Placebo on high body surface area",
          "type": "DRUG"
        },
        {
          "name": "YR001 Dose A on high body surface area twice daily",
          "type": "DRUG"
        },
        {
          "name": "YR001 Dose B on high body surface area twice daily",
          "type": "DRUG"
        },
        {
          "name": "Placebo on high body surface area twice daily",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hangzhou Yirui Pharmaceutical Technology Co., Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 54,
      "start_date": "2023-04-08",
      "completion_date": "2023-12-14",
      "has_results": false,
      "last_update_posted_date": "2024-01-24",
      "last_synced_at": "2026-10-21T22:05:45.683Z",
      "location_count": 1,
      "location_summary": "Encinitas, California",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05718921"
    },
    {
      "nct_id": "NCT01691521",
      "title": "Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Mepolizumab IV",
          "type": "DRUG"
        },
        {
          "name": "Mepolizumab SC",
          "type": "DRUG"
        },
        {
          "name": "IV Placebo",
          "type": "DRUG"
        },
        {
          "name": "SC Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 580,
      "start_date": "2012-10-08",
      "completion_date": "2014-01-18",
      "has_results": true,
      "last_update_posted_date": "2018-08-06",
      "last_synced_at": "2026-10-21T22:05:45.683Z",
      "location_count": 21,
      "location_summary": "Birmingham, Alabama • Newport Beach, California • Riverside, California + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01691521"
    },
    {
      "nct_id": "NCT00852943",
      "title": "Screening Protocol for Genetic Diseases of Allergic Inflammation",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Eosinophilic Disease",
        "Immune Deficiency",
        "HaTS",
        "Urticaria Anaphylaxis",
        "Elevated IgE Level"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Day",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "1 Day to 99 Years"
      },
      "enrollment_count": 834,
      "start_date": "2010-11-02",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-10-21T22:05:45.683Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00852943"
    }
  ]
}